Phase 1

A Study of SGN-B7H4V in Advanced Solid Tumors

Sponsor:

Seagen Inc.

Code:

NCT05194072

Conditions

Ovarian Neoplasms

Peritoneal Neoplasms

Fallopian Tube Neoplasms

Triple Negative Breast Neoplasms

HER2 Negative Breast Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SGN-B7H4V

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information